Although the majority of clinical benefits from lapatinib-based treatment were observed in patients with HER2-positive breast cancers, there are still several clinical trials of lapatinib in HER2-negative patients due to its EGFR inhibition activity [8–16]. Here, EGFR is linked to breast carcinoma.